1 / 6

Sales Forecast for Recombinate Market [Hemophilia A and B]

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

priyalclinton
Download Presentation

Sales Forecast for Recombinate Market [Hemophilia A and B]

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022byGlobalData Explore all reports for “ Hematology Therapeutics” market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  2. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Baxter’s Recombinate is a first-generation recombinant Factor VIII replacement therapy for hemophilia A patients. It is produced in CHO cells that express full-length recombinant FVIII. However, unlike Advate, Recombinate is produced in cells that are grown in the presence of human and animal serum as well as stabilized in human albumin. Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  3. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Scope Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Recombinate including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Recombinate for the top nine countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Complete report available @ http://www.rnrmarketresearch.com/recombinate-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  4. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Recombinate performance Obtain sales forecast for Recombinate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China) Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  5. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 2 Introductions 7 2.1 Catalyst 7 2.2 Related Reports 8 2.3 Upcoming Related Reports 10 3 Disease Overview 11 3.1 Etiology and Path physiology 11 3.1.1 Etiology 11 3.1.2 Path physiology 12 Inquire For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=145254 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

  6. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 For more details contact Mr. PriyankTiwari:sales@rnrmarketresearch.com/ +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnR  Market Research library has syndicated reports by leading market research  publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

More Related